78
Participants
Start Date
August 19, 2022
Primary Completion Date
October 31, 2025
Study Completion Date
March 1, 2026
CC-486
Specified dose on specified days
Placebo
Specified dose on specified days
Local Institution - 0013, Beijing
Local Institution - 0027, Beijing
Local Institution - 0005, Shenyang
Local Institution - 0020, Shenyang
Local Institution - 0017, Changchun
Local Institution - 0032, Harbin
Local Institution - 0006, Shanghai
Local Institution - 0029, Nanjing
Local Institution - 0021, Suzhou
Local Institution - 0022, Xuzhou
Local Institution - 0031, Hefei
Local Institution - 0011, Jinan
Local Institution - 0001, Tianjin
Local Institution - 0023, Tianjin
Local Institution - 0014, Hangzhou
Local Institution - 0007, Wenzhou
Local Institution - 0018, Nanchang
Local Institution - 0035, Ganzhou
Local Institution - 0034, Zhangzhou
Local Institution - 0028, Chongqing
Local Institution - 0019, Changsha
Local Institution - 0015, Changsha
Local Institution - 0004, Zhengzhou
Local Institution - 0012, Guangzhou
Local Institution - 0003, Guangzhou
Local Institution - 0008, Guangzhou
Local Institution - 0010, Shenzhen
Local Institution - 0016, Chengdu
Local Institution - 0024, Kunming
Local Institution - 0030, Xi'an
Local Institution - 0026, Lanzhou
Local Institution - 0009, Ürümqi
Local Institution - 0002, Shijiazhuang
Local Institution - 0033, Taiyuan
Lead Sponsor
Bristol-Myers Squibb
INDUSTRY